Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07647510 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
A Phase 3 study, sponsored by Dianthus Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 195
- Enrollment target
NCT07647510 is a Phase 3 study that is actively recruiting participants, run by Dianthus Therapeutics. The registered enrollment target is 195 participants.
The verdict
NCT07647510, a Phase 3 study, is actively recruiting participants, sponsored by Dianthus Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 195 participants
- Enrollment target
Study Summary
The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
Interventions
- COMBINATION_PRODUCT Placebo
- DRUG Placebo
- DRUG Claseprubart
- COMBINATION_PRODUCT Claseprubart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2026-07 |
| Est. Completion | 2031-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07647510
The ClinicalTrials.gov registry entry for NCT07647510 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dianthus Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07647510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07647510 about?
NCT07647510 is a clinical study titled "A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)". The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
What is the current status of trial NCT07647510?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 195 participants. The study started on 2026-07. Estimated completion is 2031-09.
What interventions are being tested in trial NCT07647510?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), Placebo (DRUG), Claseprubart (DRUG), Claseprubart (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07647510?
This trial is sponsored by Dianthus Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.